Evotec to collaborate with Harvard investigators; Lundbeck jumps on bullish review for depression drug;

 @FierceBiotech: In case you missed it last night: Scientists use cloning method to create embryonic stem cells. Article | Follow @FierceBiotech

 @JohnCFierce: Roche's next-gen Rituxan candidate impresses in first look at PhIII data. Report | Follow @JohnCFierce

 @RyanMFierce: @SanofiUS hunts for clinical trial recruits in growing social network. Article | Follow @RyanMFierce

> Germany's Evotec has struck a deal with Harvard to develop a new class of antibacterials. The biotech says that researchers at Harvard and Evotec will collaborate on small molecule inhibitors of bacterial cell wall synthesis, based on enabling technologies and chemical starting points licensed from Harvard. Release

> A bullish review of Lundbeck's experimental depression drug Brintellix pushed up its stock price. A JP Morgan analyst says that the treatment should carve out a place for itself with a drug tied to fewer side effects, estimating peak sales at $2.4 billion. Story

> Just days after a new strain of bird flu appeared in China, researchers for Novartis ($NVS) were able to design a new vaccine to guard against it. Story

Medical Device News

 @FierceMedDev: New special report: After tough times, hip implant revenue projected to grow again. Feature | Follow @FierceMedDev

 @MarkHFierce: Roche may be selling its glucose meter business, Reuters reports--blame competition and worsening reimbursement. Story | Follow @MarkHFierce

 @DamianFierce: In case you missed it: Hospira endured another FDA warning letter, this time over the pumps it wants to keep. Article | Follow @DamianFierce

> St. Jude snags CE mark for 3-D stent imaging. News

> Boston Scientific launches stent study for pancreatic cancer surgery. Item

> Blood Dx spots knee, hip implant allergies before procedure. DxExtra

Pharma News

 @FiercePharma: AstraZeneca advances three cancer drugs into late-stage trials. Story | Follow @FiercePharma

> WSJ: Novartis sniffs around $16B offer for Actavis. Article

> Novartis properly warned of Zometa's risks, jury decides. Story

> Colitis nod puts J&J's Simponi one step closer to blockbuster. More

Pharma Manufacturing News

> CEO of J&J OTC unit in Korea faces criminal action over plant foul-up. News

> Recalls jump 32% in first quarter. Article

> Pfizer to close Ireland plant by next year. Story

> Pfizer to pick some contract manufacturers for new elevated role. More

Vaccines News

> Taliban drops campaign against polio vaccine. News

> Human-to-human coronavirus spread looks likely. Item

> Cash injection raises hopes of diabetes vaccine. More

> Media reports used to track global vaccine backlash. Article

> Indian rotavirus vax set to undercut GSK and Merck. Story

And Finally... In what is being considered a major advancement in the field of stem cell research, scientists have created human embryonic stem cells through cloning. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.